Abstracts tagged "hypertension"

Abstract Number: 1477 • 2016 ACR/ARHP Annual Meeting
Exploring the Inadequate Cardiovascular Disease Prevention in Inflammatory Joint Diseases: Results from a Nationwide Norwegian Project
Eirik Ikdahl¹, Silvia Rollefstad², Grunde Wibetoe³, Anne Salberg⁴, Dag Magnar Soldal⁵, Inge C Olsen⁶, Tore K Kvien⁷, Anne Grete Semb¹ and Glenn Haugeberg⁸, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Martina Hansens Hospital, Bærum, Norway
Background/Purpose: Antihypertensives (antiHT) and lipid lowering therapies (LLT) prevent cardiovascular disease (CVD) effectively. It has been reported that patients with rheumatoid arthritis (RA) receive suboptimal…
Abstract Number: 1481 • 2016 ACR/ARHP Annual Meeting
Success Rate of Blood Pressure Goal Achievement in Patients with Inflammatory Joint Diseases
Silvia Rollefstad, Pia Norheim, Eirik Ikdahl and Anne Grete Semb, Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The excess risk of cardiovascular disease (CVD) in patients with inflammatory joint diseases (IJD) is attributable to several risk factors, including a high prevalence…
Abstract Number: 2051 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Cardiovascular Disease Predate the Onset of Symptoms of Rheumatoid Arthritis
Heidi Kokkonen¹, Lisbeth Ärlestig² and Solbritt Rantapää-Dahlqvist^3,4, ¹Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ²Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ⁴Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing cardiovascular (CV) comorbidity compared with the general population. Contradictory results concerning CV disease…
Abstract Number: 1539 • 2015 ACR/ARHP Annual Meeting
Control of Modifiable Cardiovascular Risk Factors in Rheumatoid Arthritis Patients Compared to Traditional High-Risk Cardiovascular Disease Patients
Brian LaMoreaux¹, Alexa Meara² and Wael N. Jarjour³, ¹Rheumatology, The Ohio State University, Columbus, OH, ²Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ³Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease affecting one percent of the population. The main cause of mortality among RA patients…
Abstract Number: 1874 • 2015 ACR/ARHP Annual Meeting
Impact of Socioeconomic Status on Survival in Connective Tissue Disease Associated and Idiopathic Pulmonary Arterial Hypertension
Helen Jin¹, John T. Granton², John Thenganatt³, Jakov Moric³, Ambika Gupta¹, Amie T. Kron¹, Cathy Chau¹ and Sindhu R. Johnson¹, ¹Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ²Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Poorer health outcomes for persons with chronic diseases have been reported in association with lower socioeconomic status (SES). No such evaluation exists for patients…
Abstract Number: 1889 • 2015 ACR/ARHP Annual Meeting
Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease
Natalie K. Kozij¹, John T. Granton², Philip E. Silkoff³, John Thenganatt⁴, Shobha Chakravorty⁴ and Sindhu R. Johnson⁵, ¹Department of Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada., Toronto, ON, Canada, ²Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Temple University, Philadelphia, PA, ⁴Respirology, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ⁵Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: We evaluated the ability of alveolar and conducting airway nitric oxide (NO) to discriminate between systemic sclerosis (SSc) with and without lung involvement, idiopathic…
Abstract Number: 2079 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Renoprotective Approaches in Lupus Nephritis: More Than Just Immunosuppression
Maite Castro¹, Eduardo Ferreira Borba¹, Michelle Lopes¹, Sandra G. Pasoto², Eloisa Bonfá¹ and Luciana Seguro², ¹Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Hypertension and persistent proteinuria are risk factors for renal disease progression and are associated with high salt intake, poor adherence to medication and smoking.…
Abstract Number: 2095 • 2015 ACR/ARHP Annual Meeting
Dietary Patterns (DASH, Prudent, Western Diets) and the Risk of Gout in US Women – the Nurses Health Study
Jeewoong Choi¹, Na Lu², Yuqing Zhang³, Sharan K. Rai⁴, Gary C. Curhan⁵ and Hyon K. Choi², ¹Massachusetts College of Pharmacy and Health Sciences, Boston, MA, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³BUSM, Boston, MA, ⁴Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁵Renal Division, Brigham and Women's Hospital, Boston, MA
Background/Purpose: There is a remarkable, rising disease burden of gout and associated cardiovascular-metabolic comorbidities (e.g., hypertension in 74% and obesity in 53% of cases in…
Abstract Number: 2242 • 2015 ACR/ARHP Annual Meeting
Compliance with Allopurinol Among Hypertensive Patients with Gout Diagnosis and the Relationship to Onset of End-Stage Renal Disease
Sylvie Perreault¹, Javier Nuevo², Scott Baumgartner³ and Robert Morlock⁴, ¹University of Montreal, Montreal, QC, Canada, ²AstraZeneca, Madrid, Spain, Madrid, Spain, ³Ardea Biosciences, Inc., San Diego, CA, ⁴4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: The risk of end-stage renal disease (ESRD) in both hypertension and gout has been examined in the clinical literature. However, the impact of allopurinol…
Abstract Number: 2737 • 2015 ACR/ARHP Annual Meeting
Consistency of Treatment Effects Across Different High-Risk Clinical Phenotypes in the Tofacitinib Clinical Program
Jeffrey R. Curtis¹, Ara Dikranian², Alan Mendelsohn³, Koshika Soma⁴, Haiyun Fan³ and Chudy Nduaka³, ¹University of Alabama at Birmingham, Birmingham, AL, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients (pts) with RA often have comorbidities that may affect treatment response.…
Abstract Number: 910 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-Alpha Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Rishi J. Desai¹, Daniel H. Solomon², Sebastian Schneeweiss³, Goodarz Danaei⁴, Katherine Liao⁵ and Seoyoung C. Kim⁶, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Harvard School of Public Health, Boston, MA, ⁵Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Results from several small studies support the potential blood pressure lowering effect of tumor necrosis factor (TNF)-a inhibitors in rheumatoid arthritis (RA) patients. Yet,…
Abstract Number: 1498 • 2015 ACR/ARHP Annual Meeting
Engaging Clinic Staff in Work System Redesign to Adapt a Hypertension Protocol for Rheumatology
Edmond Ramly¹, Diane Lauver² and Christie M. Bartels³, ¹Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, ²University of Wisconsin-Madison School of Nursing, Madison, WI, ³Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health (SMPH), Madison, WI
Background/Purpose: Despite routine blood pressure (BP) measurement by clinic staff, we reported that rheumatologists discussed elevated BPs in <1/3 of visits leading to missed opportunities…
Abstract Number: 1506 • 2015 ACR/ARHP Annual Meeting
EULAR Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Inflammatory Joint Diseases – 2015 Update
Michael T. Nurmohamed and on behalf of the EULAR task force "EULAR Recommendations for Cardiovascular Risk Management in patients with Rheumatoid Arthritis and other Inflammatory Joint Diseases", Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) (and other inflammatory joint diseases (IJD)) have an increased cardiovascular (CV) risk. In 2009 a EULAR taskforce recommended screening,…
Abstract Number: 1678 • 2014 ACR/ARHP Annual Meeting
Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort
Matthew R. Lammi¹, Lesley Ann Saketkoo², Stephen C. Mathai³, Robyn T. Domsic⁴, Christine M. Bojanowski⁵, Virginia D. Steen⁶, Daniel E. Furst⁷ and Pharos Investigators⁸, ¹Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³Medicine, Johns Hopkins University, Baltimore, MD, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Internal Medicine and Pediatrics, LSU Health Sciences Center, New Orleans, LA, ⁶Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁷University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁸Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc). Although medications have improved their prognosis, optimal therapy remains undefined.…
Abstract Number: 1635 • 2014 ACR/ARHP Annual Meeting
Association Between Carrying at Least One Apolipoprotein1 Variant Allele and Hypertension in Lupus Patients with Normal Renal Function
Ashira Blazer¹, H. Michael Belmont², Robert Clancy³, Peter M. Izmirly⁴ and Jill P. Buyon⁵, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Rheumatology, NYU Medical Center, New York, NY, ⁴Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose The apolipoprotein1 (APOL1) gene encodes a 3 domain protein found both in serum and intracellularly in endothelial cells among other cell types. Variant APOL1…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].